News & Events

For Immediate Release

Bookmark & Share
Contact: Kathryn Ryan, 914-740-2100, kryan@liebertpub.com
Home Use of Hybrid Closed-Loop Insulin Delivery System Shown Safe and Effective for Adolescents and Adults

New Rochelle, NY, February 13, 2017—A pivotal registration trial to evaluate in-home use of the Medtronic MiniMed® 670G hybrid closed-loop insulin delivery system over 3 months showed a significant reduction in HbA1c levels for both adolescents and adults with type 1 diabetes. None of the participants experienced a severe hypoglycemic or diabetic ketoacidosis event, demonstrating the safety of system, as reported in an article published in Diabetes Technology & Therapeutics (DTT), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the DTT website.

The article entitled "Glucose Outcomes with the In-home Use of a Hybrid Closed-loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes," is coauthored by Satish Garg, MD, University of Colorado Denver (Aurora) and DTT Editor-in-Chief, and a team of researchers from Yale University (New Haven, CT), Stanford University (CA), Atlanta Diabetes Associates (GA), AMCR Institute (Escondido, CA), Rainier Clinical Research Center (Renton, WA), Sheba Medical Center (Tel Hashomer, Israel), University of Virginia (Charlottesville, VA), International Diabetes Center (Minneapolis, MN), and Medtronic (Northridge, CA).

The researchers reported a significant decrease in the time participants spent in hypoglycemia and, similarly, a significant increase in the proportion of sensor glucose readings that were in the target range (71-180 mg/dL) during the study period for both adults and adolescents. Adult subjects used the system with Auto Mode (hybrid closed-loop) enabled for a median 88% of the time (>21 hrs/day). The MiniMed® 670G hybrid closed-loop system automatically increases, decreases, and suspends insulin delivery in response to continuous glucose monitoring.


About the Journal
Diabetes Technology & Therapeutics (DTT) is a monthly peer-reviewed journal that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its complications. Led by Editor-in-Chief Satish Garg, MD, the Journal covers topics that include noninvasive glucose monitoring, implantable continuous glucose sensors, novel routes of insulin administration, genetic engineering, the artificial pancreas, measures of long-term control, computer applications for case management, telemedicine, the Internet, and new medications. Tables of contents and a free sample issue may be viewed on the Diabetes Technology & Therapeutics (DTT) website. DTT is the official journal of the Advanced Technologies & Treatments for Diabetes (ATTD) Conference.
About ATTD
The International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) presents top caliber scientific programs that have provided participants with cutting-edge research and analysis into the latest developments in diabetes-related technology. A unique and innovative conference, ATTD brings the world’s leading researchers and clinicians together for a lively exchange of ideas and information related to the technology, treatment, and prevention of diabetes and related illnesses.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Thyroid, Metabolic Syndrome and Related Disorders, Journal of Aerosol Medicine and Pulmonary Drug Delivery, Childhood Obesity, and Population Health Management. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.